Loading...
NPI 1609078427 · Camp Hill, PA · Ophthalmology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Lawrence Ho is a ophthalmology physician provider located in Camp Hill, Pennsylvania. This profile covers 15 Medicare and 2 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Lawrence Ho |
| Address | 220 Grandview Ave |
| City | Camp Hill |
| State | PA |
| ZIP | 17011 |
| Taxonomy | Ophthalmology Physician |
| NPI Enumerated | June 4, 2007 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $3M |
| Medicaid | $4.1K |
This provider is effectively Medicare‑dominant: total Medicare revenue is $3M while total Medicaid revenue is $4.1K, indicating Medicare drives nearly all billed revenue and Medicaid activity is negligible in scale. Analysts should treat the Medicaid channel as a very small part of the payer mix when modeling volume or negotiating Medicaid rates.
Medicare revenue is highly concentrated in intravitreal biologic therapies: the top 3 Medicare codes by revenue (J2777, J0178, J2778) account for 87.8% of this provider's total Medicare revenue, with J2777 at $1.3M (44.2%), J0178 at $970.2K (32.1%), and J2778 at $347.5K (11.5%). These codes are all anti‑VEGF / intravitreal injection agents, so the practice appears to operate primarily as a retina-focused injection/service line rather than a broad general ophthalmology clinic.
The Medicaid revenue picture is similarly concentrated but very small in absolute terms: the top 3 Medicaid codes by revenue account for 100.0% of Medicaid revenue, led by 92134 at $2.6K (63.5%) and 67028 at $1.5K (36.5%). While concentrated on retinal imaging and intravitreal injections, the total Medicaid dollars ($4.1K) are immaterial compared with Medicare and unlikely to alter overall service‑line economics.
Competitive standing on the drug codes is not dominant nationally despite large dollars: J2777 ranks #128 of 2039 providers nationally (94th percentile; typical, unremarkable volume for this code), J0178 ranks #897 of 3204 providers nationally (72th percentile; typical, unremarkable volume for this code), and J2778 ranks #231 of 1208 providers nationally (81th percentile; typical, unremarkable volume for this code). In short, the provider posts sizable drug revenue but appears as a typical participant among peers who deliver intravitreal biologics rather than as a clear national leader.
There is a clear operational emphasis on clinic throughput and follow‑up visits: 99213 has 1.2K claims and $77.9K revenue (2.6%) and is flagged as an extreme statistical outlier, ranking #3727 of 457151 providers nationally (99th percentile; extreme outlier, far above typical national volume). The unusually high E/M claim volume relative to national peers suggests heavy recurring visit activity consistent with serial injection protocols and frequent monitoring.
Retinal imaging activity is elevated on Medicare but not on Medicaid: 92134 has 2.3K claims and $63.3K revenue (2.1%) on Medicare and ranks #818 of 26868 providers nationally (97th percentile; notably above typical national volume), while the same code on Medicaid (152 claims, $2.6K, 63.5%) ranks #116 of 183 in‑state (37th percentile; typical, unremarkable volume for this code). This divergence indicates the provider relies on advanced retinal imaging for Medicare patients at levels above national norms, whereas imaging for Medicaid patients is routine and limited by the program’s small share of overall volume.
Supporting procedure codes align with an injection‑center workflow: 67028 appears on both payers (Medicare: 1.9K claims, $161K revenue (5.3%); Medicaid: 28 claims, $1.5K revenue (36.5%)) and 92134 appears as a frequent diagnostic code, confirming a service mix of intravitreal injections plus diagnostic retinal imaging. Together these procedure and drug codes characterize an operation centered on injectable biologic treatments with associated monitoring, rather than a general surgical ophthalmology profile.
Tenure and market presence: the NPI was enumerated on 2007-06-04 (~19 years ago), indicating an established practice footprint. Given long tenure plus a revenue mix concentrated in repeat intravitreal therapies and high E/M throughput, payers and competitors should treat this provider as an experienced retinal injection clinic with predictable, recurring Medicare revenue streams tied to biologic drug utilization.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
15 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J2777 | Injection, faricimab‑svoa, 0.1 mg | 45,960 | $30 | $1.3M |
| J0178 | Injection, aflibercept, 1 mg | 1,400 | $690 | $970.2K |
| J2778 | Injection, ranibizumab, 0.1 mg | 1,920 | $180 | $347.5K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 1,940 | $80 | $161K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 1,240 | $60 | $77.9K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 2,260 | $30 | $63.3K |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 240 | $90 | $20.9K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 150 | $90 | $13.6K |
| 92004 | The provider performs a comprehensive level ophthalmological evaluation of a new patient and initiates a diagnostic and treatment program for one or more visits. | 100 | $100 | $9.8K |
| J7999 | Compounded drug, not otherwise classified | 90 | $70 | $6.1K |
Showing 1–10 of 15
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 15 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
15 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J0178 | 47 | 140 | 830 | $690 | $865.1K |
| J2778 | 24 | 70 | 1,030 | $190 | $417.1K |
| J2777 | 2 | 100 | 7,950 | $30 | $360.2K |
| 67028 | 30 | 180 | 600 | $90 | $87.5K |
| J7999 | 61 | 110 | 100 | $120 | $33.3K |
| 92014 | 504 | 1,570 | 130 | $80 | $21K |
| 99214 | 8,716 | 23,230 | 100 | $80 | $14.5K |
| 92235 | 40 | 70 | 40 | $100 | $10K |
| 92134 | 36 | 1,320 | 60 | $30 | $8.4K |
| 99213 | 91 | 22,370 | 70 | $60 | $7.7K |
Showing 1–10 of 15
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
2 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 150 | $20 | $2.6K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 30 | $50 | $1.5K |
How this provider's Medicaid billing volume and revenue compare to other Pennsylvania providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Pennsylvania median
2 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 91 | 100 | 330 | $70 | $85.4K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 116 | 180 | 290 | $20 | $24.8K |
Other providers in the same ZIP code as Lawrence Ho, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Medstaffers, LLC | PA | Home Health Agency | $0 | $15.1M |
| Penn State Health Holy Spirit Medical Center | PA | General Acute Care Hospital | $0 | $10.2M |
| Penn State Health Life Lion, LLC | PA | Ambulance | $2.4M | $6.9M |
| Shadai Healthcare Services LLC | PA | Home Health Agency | $0 | $9.2M |
| Rajesh Dave | PA | Cardiovascular Disease Physician | $934K | $0 |
| West Shore Endoscopy Center LLC | PA | Ambulatory Surgical Clinic/Center | $770.4K | $66.2K |
| Jihua Cheng | PA | Hematology & Oncology Physician | $685.8K | $0 |
| Daniel Kim | PA | Orthopaedic Surgery Physician | $451K | $2.2K |
| Kumudini Rao | PA | Hematology & Oncology Physician | $444K | $0 |
| Henry Venbrux | PA | Anatomic Pathology & Clinical Pathology Physician | $416.5K | $18.3K |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.